Document:

Exhibit

Exhibit 10.11

December 9, 2016
Christopher J. Gostout
182 Evergreen Dr. NE 
Rochester, MN 55906 
Dear CJ: 
Apollo Endosurgery, Inc. (“Apollo” or the “Company”) is extremely pleased to provide an offer of employment with our company in the position of a Chief Medical Officer. This offer letter supersedes all other communications verbal or written.  We expect that your employment as a salaried employee, generally devoting up to 75% of your time, with the Company will start on or about Tuesday, January 2, 2017, subject to your approval of the terms hereof.    
As a Chief Medical Officer, you will report to Apollo’s CEO and you shall have duties and authority as are customarily performed by a Chief Medical Officer of a company similar in size and business as Apollo Endosurgery as described in the description of duties attached as Exhibit A. You will be responsible for working in adherence to Apollo’s quality systems including completing new hire training within 90 days of employment and additional training within the timelines and standards of Apollo’s training policies. Your responsibilities may be adjusted from time to time depending on facts and circumstances.  You will be based out of your home office in Rochester, MN and will be present at the Apollo’s Corporate Offices and other destinations as business needs dictate.   
As an Apollo employee, you will receive the following:
		
	•
	Salary: Upon employment, you will receive a starting salary of $9,166.67 per pay period (before applicable withholding and taxes) as your base salary to be paid on the Company’s regular paydays on a semi-monthly basis (24 pay cycles per year and pay dates are typically the 15th and last day of the month.

		
	•
	Annual Bonus: You will be eligible to participate in Apollo’s Corporate Bonus Plan. You will be eligible to receive an annual bonus of up to 30% of your then current base salary, payable in accordance with the Company’s standard policies and practices. Your annual bonuses will be based upon mutually agreed upon milestones and other relevant criteria; however, the decision of whether or not such criteria have been achieved and the determination to pay annual bonuses each year is solely within the discretion of the Board of Directors of the Company.

		
	•
	Employment Stock Options:  You will be granted an Incentive Stock Option to purchase the equivalent of 1% of fully diluted shares of Company Common Stock at the time of grant, which is subject to Board of Director approval.  The actual number of shares you will be granted will be determined upon completion of the Company’s pending merger with LPath, Inc. The granting of these options will be governed by the Company's 2016 Stock Option Plan and an option agreement, which the Company will provide you upon request or when you receive your grant.  These documents will govern and control your options and any stock issued upon exercise of your options.  You should look to these documents for a complete description of the option’s terms, but, to summarize, the exercise price of your options will be equal to the fair market value per share of Company’s Common Stock on the date of grant, as approved by Company’s Board of Directors.  The initial vesting of 25% of the shares subject to the option will occur at the one year anniversary of the date of your employment, and the remaining shares subject to the option will vest thereafter in equal monthly installments over thirty-six (36) months, based on continued employment.

		
	•
	Vacation:  You will be eligible for the Company’s vacation plan that typically accumulates ten (10) hours per month for full time employees.  As previously agreed with you, the company is flexible with regard to the time off you may take and understands you may exceed the accumulated amount noted in the standard vacation policy with approval from the CEO.   In addition, per the company’s policies, you will be entitled to ten (10) days of personal leave (sick time) per calendar year, which will not carry over to the next calendar year, prorated based on date of hire.

		
	•
	Health Care Plan and Other Benefits:  You will be entitled to participate in the Company’s health care plan and all of the other Company standard benefits on the first of the month following your start date.

		
	•
	Travel and Other Expenses:  You will be entitled to reimbursement by the Company for all reasonable travel, lodging, and other expenses actually incurred in connection with the performance of your duties, against receipts or other appropriate written evidence of such expenditures as required.

The Company requires all job candidates to complete a standard background / reference check and to undergo screening for the presence of illegal drugs as a condition for employment. This offer is contingent upon satisfactory completion of both requirements.  In the event that employment commences prior to the Company’s receipt of any such screening reports, it is the understanding of the employee and the Company that the employee will be immediately discharged in the event of an unsatisfactory result.  
You will be required to execute the Company’s standard Invention, Confidential Information and Non-Competition Agreement.  As part of this agreement you will be required to list any inventions or intellectual property that you have previously developed.  
As per the Apollo Code of Business Conduct and Ethics Policy, any Apollo employee may not provide services to parties who are a customer, supplier or competitor of Apollo or to have other business relationships that present a conflict of interest.  Prior to your start date, Apollo will need to understand the scope of any activities that you plan to continue following your start date and these activities will need to be approved by Apollo.  
For purposes of federal immigration laws, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States.  Such documentation must be provided within 3 business days of the effective date of your employment, or your employment relationship with the Company will be terminated. 
Your employment relationship with Apollo will be what is called “at will.”  That is, even after accepting this employment offer, you will have the right to quit at any time, and the Company will have the right to end your employment relationship with the Company for any reason, with or without cause, or for no reason.  Of course we hope everything works out for the best, but the Company wants to make sure that you understand that nothing in this letter or in any Company policy or statement (including any other written or verbal statements made to you during negotiations about working at Apollo) is intended to or does create anything but an at will employment relationship. Only the Company's Board of Directors may modify your at-will employment status, or guarantee that you will be employed for a specific period of time. Such modification must be in writing, approved by the Board of Directors, and signed by an authorized Company representative. 
You agree that you will not use in the performance of your duties, nor disclose to any Apollo employee, any confidential information or trade secrets of any former employer or other person which would violate your legal obligations to those parties. Performance of your duties at Apollo will only require information and knowledge which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by Apollo. 
The terms and conditions of the offer reflected will remain open until the earlier of the execution of this letter and the Invention, Confidential Information and Non-Competition Agreement or until the close of business on Tuesday, December 20, 2016, unless revoked before then by the Company. Upon execution, this letter, together with the Invention, Confidential Information and Non-Competition Agreement, contains the entire agreement among the parties relating to your proposed employment with the Company and supersedes any previous agreements, including consulting agreements, communications or offers of any kind, written or verbal, between the parties. 
We are excited about you joining the Apollo team. We believe that you can make a significant contribution to the success of the Company and are eager to have you join us and help us revolutionize surgery. 

Sincerely,
/s/ Mary League

Mary League 
Vice President, Human Resources

Accepted and agreed:

Christopher J. Gostout
Employee Name - printed

/s/Christopher J. Gostout
Employee Name - signature

Date: December 27, 2016Exhibit

Exhibit 10.26

SIXTH AMENDMENT TO CREDIT AGREEMENT
THIS SIXTH AMENDMENT TO CREDIT AGREEMENT (this “Agreement”) dated as of February 28, 2018 is entered into among APOLLO ENDOSURGERY US, INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and ATHYRIUM OPPORTUNITIES II ACQUISITION LP, as Administrative Agent (the “Administrative Agent”).  All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Credit Agreement (as defined below).
RECITALS
WHEREAS, the Borrower, the Guarantors party thereto, the Lenders from time to time party thereto and the Administrative Agent have entered into that certain Credit Agreement dated as of February 27, 2015 (as amended, restated, supplemented or modified from time to time, the “Credit Agreement”);
WHEREAS, the Borrower has requested that the Lenders amend the Credit Agreement as set forth below; and
WHEREAS, the Lenders and the Administrative Agent are willing to amend the Credit Agreement as set forth below, subject to the terms and conditions set forth below.
NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1.    Amendments.  
(a)    Section 8.16(a) of the Credit Agreement is hereby amended to read as follows:
(a)    [Reserved].  
(b)    Section 8.16(b) of the Credit Agreement is hereby amended to read as follows:
(b)    Consolidated Debt to Revenues Ratio.  Permit the Consolidated Debt to Revenues Ratio as of the end of any fiscal quarter of the Parent (or, with respect to any fiscal quarter ending prior to the Transaction Closing Date, the Borrower) to be greater than (i) 0.60 to 1.0, for any fiscal quarter ending during the period from the Closing Date to and including June 30, 2015, (ii) 0.76 to 1.0, for any fiscal quarter ending during the period from July 1, 2015 to and including June 30, 2016, (iii) 0.80 to 1.0, for the fiscal quarter ending September 30, 2016, (iv) 0.80 to 1.0, for the fiscal quarter ending December 31, 2016, (v) 0.65 to 1.0, for the fiscal quarter ending March 31, 2017, (vi) 0.61 to 1.0, for the fiscal quarter ending June 30, 2017, (vii) 0.57 to 1.0, for the fiscal quarter ending September 30, 2017, (viii) 0.53 to 1.0, for the fiscal quarter ending December 31, 2017, (ix) 0.54 to 1.0, for the fiscal quarter ending March 31, 2018, (x) 0.53 to 1.0, for the fiscal quarter ending June 30, 2018, (xi) 0.52 to 1.0, for the fiscal quarter ending September 30, 2018, (xii) 0.51 to 1.0, for the fiscal quarter ending December 31, 2018, (xiii) 0.49 to 1.0, for the fiscal quarter ending March 31, 2019, (xiv) 0.46 to 1.0, for the fiscal quarter ending June 30, 2019, (xv) 0.43 to 1.0 for the fiscal quarter ending September 30, 2019, and (xvi) 0.40 to 1.0, for any fiscal quarter ending thereafter.
(c)    Exhibit E to the Credit Agreement is hereby amended to read as set forth on Exhibit E attached hereto.
2.    Conditions Precedent.  This Agreement shall be effective upon satisfaction of the following conditions precedent: 
(a)    receipt by the Administrative Agent of counterparts of this Agreement duly executed by the Borrower, the Guarantors, the Lenders and the Administrative Agent;

(b)    receipt by the Administrative Agent of an amendment fee in the amount of $338,829.16; and
(c)    payment by the Borrower of all fees, charges and disbursements of counsel to the Administrative Agent incurred in connection with the preparation, execution and delivery of this Agreement.
3.    Reaffirmation.  Each of the Loan Parties acknowledges and reaffirms (a) that it is bound by all of the terms of the Investment Documents to which it is a party and (b) that it is responsible for the observance and full performance of all Obligations, including without limitation, the repayment of the Term Loan.  Furthermore, the Loan Parties acknowledge and confirm (i) that the Lenders have performed fully all of their obligations under the Credit Agreement and the other Investment Documents and (ii) that by entering into this Agreement, the Lenders do not, except as expressly set forth herein, waive or release any term or condition of the Credit Agreement or any of the other Investment Documents or any of their rights or remedies under such Investment Documents or any applicable law or any of the obligations of the Loan Parties thereunder.
4.    Miscellaneous.
(a)    The Credit Agreement and the obligations of the Loan Parties thereunder and under the other Investment Documents, are hereby ratified and confirmed and shall remain in full force and effect according to their terms.  This Agreement is a Loan Document.
(b)    Each Guarantor (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of its obligations under the Loan Documents, and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge its obligations under the Credit Agreement or the Loan Documents.
(c)    The Loan Parties represent and warrant to the Lender that:
(i)    each Loan Party has taken all necessary corporate or other organizational action to authorize the execution, delivery and performance of this Agreement.
(ii)    this Agreement has been duly executed and delivered by each Loan Party and constitutes a legal, valid and binding obligation of each Loan Party, enforceable against each such Loan Party in accordance with its terms, subject to bankruptcy, insolvency and similar laws affecting enforceability of creditors’ rights generally and to general principles of equity.
(iii)    no approval, consent, exemption, authorization or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Loan Party of this Agreement.
(iv)    (A) the representations and warranties of the Borrower and each other Loan Party contained in Article VI of the Credit Agreement or any other Investment Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (and in all respects if any such representation and warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (and in all respects if any such representation and warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date and (B) no event has occurred and is continuing which constitutes a Default or an Event of Default.
(d)    This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page of this Agreement by facsimile or other electronic imagine means (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Agreement.

(e)    If any provision of this Agreement is held to be illegal, invalid or unenforceable, (i) the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby and (ii) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
(f)    THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.
	
			
	BORROWER:
	 
	APOLLO ENDOSURGERY US, INC.

	 
	 
	a Delaware Corporation

	 
	 
	 

	 
	 
	By: /s/Stefanie Cavanaugh

	 
	 
	Title: Chief Financial Officer

	
			
	GUARANTORS:
	 
	APOLLO ENDOSURGERY, INC.,

	 
	 
	a Delaware Corporation

	 
	 
	 

	 
	 
	By: /s/Stefanie Cavanaugh

	 
	 
	Title: Chief Financial Officer

	 
	 
	 

	 
	 
	 

	 
	 
	APOLLO ENDOSURGERY INTERNATIONAL, LLC,

	 
	 
	a Delaware Corporation

	 
	 
	 

	 
	 
	By: /s/Stefanie Cavanaugh

	 
	 
	Title: Chief Financial Officer

	 
	 
	 

	 
	 
	 

	 
	 
	LPATH THERAPEUTICS, INC.,

	 
	 
	a Delaware Corporation

	 
	 
	 

	 
	 
	By: /s/Stefanie Cavanaugh

	 
	 
	Title: Chief Financial Officer

	
			
	ADMINISTRATIVE AGENT:
	 
	ATHRIUM OPPORTUNITIES II ACQUISITION LP,

	 
	 
	a Delaware limited partnership

	 
	 
	 

	 
	 
	By: ATHYRIUM OPPORTUNITIES ASSOCIATES II LP,

	 
	 
	its General Partner

	 
	 
	 

	 
	 
	     By: ATHYRIUM GP HOLDINGS LLC, its General

	 
	 
	           Partner

	 
	 
	 

	 
	 
	          By:/s/ Andrew C. Hyman

	 
	 
	          Name: Andrew C. Hyman

	 
	 
	          Title: Authorized Signatory

	 
	 
	 

	LENDERS:
	 
	ATHRIUM OPPORTUNITIES II ACQUISITION LP,

	 
	 
	a Delaware limited partnership

	 
	 
	 

	 
	 
	By: ATHYRIUM OPPORTUNITIES ASSOCIATES II LP,

	 
	 
	its General Partner

	 
	 
	 

	 
	 
	     By: ATHYRIUM GP HOLDINGS LLC, its General

	 
	 
	           Partner

	 
	 
	 

	 
	 
	          By:/s/ Andrew C. Hyman

	 
	 
	          Name: Andrew C. Hyman

	 
	 
	          Title: Authorized Signatory

Exhibit E

FORM OF Compliance Certificate

Financial Statement Date: __________, 20    

To:    Athyrium Opportunities II Acquisition LP, as Administrative Agent

		
	Re:
	Credit Agreement dated as of February 27, 2015 (as amended, modified, restated, supplemented or extended from time to time, the “Credit Agreement”) among Apollo Endosurgery US, Inc., a Delaware corporation (the “Borrower”), the Guarantors, the Lenders from time to time party thereto and Athyrium Opportunities II Acquisition LP, as Administrative Agent.  Capitalized terms used but not otherwise defined herein have the meanings provided in the Credit Agreement.

Date:                    

Ladies and Gentlemen:

The undersigned Responsible Officer hereby certifies as of the date hereof that [he][she] is the _______________ of Apollo Endosurgery, Inc., a Delaware corporation (the “Parent”), and that, in [his][her] capacity as such, [he][she] is authorized to execute and deliver this Compliance Certificate to the Administrative Agent on the behalf of the Parent, and that:

[Use following paragraph 1 for fiscal year‐end financial statements:]

[1.    Attached hereto as Schedule 1 are the year‐end audited financial statements required by Section 7.01(a) of the Credit Agreement for the fiscal year of the Parent ended as of the above date, together with the report and opinion of an independent certified public accountant required by such Section.]

[Use following paragraph 1 for fiscal quarter‐end financial statements:]

[1.    Attached hereto as Schedule 1 are the unaudited financial statements required by Section 7.01(b) of the Credit Agreement for the fiscal quarter of the Parent ended as of the above date.  Such financial statements fairly present in all material respects the financial condition, results of operations, shareholders’ equity and cash flows of the Parent and its Subsidiaries in accordance with GAAP as at such date and for such period, subject only to normal year-end audit adjustments and the absence of footnotes.]

[Use following paragraph 1 for financial statements delivered for the last calendar month of any fiscal year:]

[1.    Attached hereto as Schedule 1 are the unaudited financial statements required by Section 7.01(c) of the Credit Agreement for the calendar month of the Parent ended as of the above date.  Such financial statements fairly present in all material respects the financial condition, results of operations, shareholders’ equity and cash flows of the Parent and its Subsidiaries in accordance with GAAP as at such date and for such period, subject only to normal year-end audit adjustments and the absence of footnotes.]

2.    The undersigned has reviewed and is familiar with the terms of the Credit Agreement and has made, or has caused to be made, a reasonably detailed review of the transactions and condition (financial or otherwise) of the Parent during the accounting period covered by the attached financial statements.

3.    A review of the activities of the Parent during such fiscal period has been made under the supervision of the undersigned with a view to determining whether during such fiscal period the Parent and its Subsidiaries performed and observed all of its obligations under the Investment Documents, and 

[select one:]

[to the best knowledge of the undersigned during such fiscal period, the Parent and its Subsidiaries performed and observed each covenant and condition of the Investment Documents applicable to it, and no Default has occurred and is continuing.]

[or:]

[the following covenants or conditions have not been performed or observed and the following is a list of each such Default and its nature and status:]

4.    The financial covenant analyses and calculation of the Consolidated Debt to Revenues Ratio set forth on Schedule 2 attached hereto are true and accurate on and as of the date of this Compliance Certificate.

[5.    Attached hereto as Schedule 3 is a supplement setting forth information regarding the amount of all Dispositions, Involuntary Dispositions, Debt Issuances, Extraordinary Receipts and Acquisitions that occurred during the period covered by the financial statements attached hereto as Schedule 1.] To be included for Compliance Certificate delivered in connection with financial statements pursuant to Section 7.01(a) or (b).

[6.    Attached hereto as Schedule 4 is (i) a list of (A) all applications by any Loan Party, if any, for Copyrights, Patents or Trademarks made since [the Closing Date] [the date of the prior Compliance Certificate], (B) all issuances of registrations or letters on existing applications by any Loan Party for Copyrights, Patents and Trademarks received since [the Closing Date] [the date of the prior Compliance Certificate], (C) all Trademark Licenses, Copyright Licenses and Patent Licenses entered into by any Loan Party since [the Closing Date] [the date of the prior Compliance Certificate] and (D) such supplements to Schedule 6.17 as are necessary to cause such schedule to be true and complete as of the date of such certificate and (ii) the insurance binder or other evidence of insurance for any insurance coverage of any Loan Party or any Subsidiary that was renewed, replaced or modified during the period covered by the financial statements attached hereto as Schedule 1.] To be included for Compliance Certificate delivered in connection with financial statements pursuant to Section 7.01(a) or (b).

1 To be included for Compliance Certificate delivered in connection with financial statements pursuant to Section 7.01(a) or (b).
2 To be included for Compliance Certificate delivered in connection with financial statements pursuant to Section 7.01(a) or (b).

IN WITNESS WHEREOF, the undersigned has executed this Compliance Certificate as of the date set forth above.

Apollo Endosurgery, Inc.,
a Delaware corporation
By:                    
Name:
Title:

Schedule 1

Schedule 2

Consolidated Debt to Revenues Ratio.
	
					
	A. Consolidated Funded Indebtedness
	 

	 
	i.
	all obligations, whether current or long-term, for borrowed money (including the Obligations) and all obligations of the Parent and its Subsidiaries evidenced by bonds, debentures, notes, loan agreements or other similar instruments
	$___________
	 

	 
	ii.
	all purchase money Indebtedness 
	$___________
	 

	 
	iii.
	the principal portion of all obligations under conditional sale or other title retention agreements relating to property purchased by the Parent and its Subsidiaries thereof (other than customary reservations or retentions of title under agreements with suppliers entered into in the ordinary course of business)
	$___________
	 

	 
	iv.
	all obligations arising under letters of credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments
	$___________
	 

	 
	v.
	all obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business and, in each case, not past due for more than 60 days after the date on which such trade account payable was created), including, without limitation, any Earn Out Obligations
	$___________
	 

	 
	vi.
	the Attributable Indebtedness of Capital Leases, Securitization Transactions and Synthetic Leases
	$___________
	 

	
				
	 
	 
	 
	 

	 
	vii.
	all obligations of the Parent and its Subsidiaries to purchase, redeem, retire, defease or otherwise make any payment in respect of any Equity Interests in the Parent or its Subsidiaries or any other Person (excluding the Permitted Preferred Stock for so long as such Equity Interests constitute “Permitted Preferred Stock” in accordance with the definition thereof), valued, in the case of a redeemable preferred interest, at the greater of its voluntary or involuntary liquidation preference plus accrued and unpaid dividends
	$___________

	 
	viii.
	all Funded Indebtedness of others secured by (or for which the holder of such Funded Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on, or payable out of the proceeds of production from, property owned or acquired by the Parent and its Subsidiaries, whether or not the obligations secured thereby have been assumed
	$___________

	 
	ix.
	all Guarantees with respect to Funded Indebtedness of the types specified in (i) through (viii) above of another Person
	$___________

	 
	x.
	all Funded Indebtedness of the types referred to in (i) through (ix) above of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which the Parent or any of its Subsidiaries is a general partner or joint venturer, except to the extent that Funded Indebtedness is expressly made non-recourse to the Parent or any of its Subsidiaries
	$___________

	 
	xii.
	Sum of (i) + (ii) + (iii) + (iv) + (v) + (vi) + (vii) + (viii) + (ix) + (x)
	$___________

	
			
	 
	 
	 

	B. Annualized Consolidated Revenues for the preceding period of two fiscal quarters
	$___________

	 
	 
	 

	C. Cure Amount
	$___________

	 
	 
	 

	D. Consolidated Debt to Revenues Ratio
     [(A)(xi) / ((B) + (C))]
	_____ : 1.0

	 
	 
	 

	Ratio required by Section 8.16(b) of the Credit Agreement for such fiscal quarter:
	$

	Compliance:
	                              [Yes] [No]

Schedule 3
Schedule 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]